Latest Recruitment News

Platina Resources has launched an extensive 2026 drilling campaign across its Laverton gold portfolio, while advancing key acquisitions to nearly double its landholding and navigating leadership changes.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.

MRG Metals’ joint venture partner Sinowin Lithium has delivered a comprehensive Environmental and Social Impact Assessment for the Corridor Central Titanium Dioxide project in Mozambique, marking a key regulatory milestone towards production in 2027.

CLINUVEL Pharmaceuticals has received final scientific advice from the European Medicines Agency on the design of its pivotal Phase III trial for SCENESSE in vitiligo, endorsing a comprehensive evidence approach and prioritising patients with darker skin tones.

PLS Group delivered a record 232.4kt spodumene concentrate production in March 2026, lifted revenue 52% to A$567 million on soaring lithium prices, and strengthened its balance sheet with a US$600 million senior notes issuance.

Cambium Bio has secured FDA confirmation that a single pivotal Phase 3 trial plus confirmatory evidence will suffice for Biologics License Application submission for Elate Ocular, significantly reducing development expenses and accelerating the pathway to market.

Cavalier Resources has secured a $4 million placement at an 11.95% discount to the 15-day VWAP, funding critical pre-production activities at its Crawford Gold Project. This capital injection complements ongoing negotiations for a US$13 million gold prepayment and a A$5 million loan, advancing the project toward production.

Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.

Metal Powder Works nearly doubled its powder revenue in Q1 2026 while maintaining strong margins, secured its first NATO defence contract under the UK Ministry of Defence’s Project TAMPA, and advanced its Next Gen powder production system on schedule.

Kaiser Reef reports promising drilling results and key infrastructure upgrades at its Maldon Gold Project, setting the stage for expanded exploration and production in Victoria’s historic gold district.

Firebrick Pharma secured regulatory approval for Nasodine Nasal Spray in Indonesia and launched Nasodine Throat Spray in Singapore and Fiji, while raising $1.5 million to fuel growth. The company aims to quadruple its product and market footprint within three years.

Invion Limited is broadening its non-melanoma skin cancer trial to include basal cell carcinoma patients following encouraging safety and efficacy data from squamous cell carcinoma cohorts, targeting the largest skin cancer segment.